Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetic dyslipidaemia.

D J Betteridge1

  • 1Department of Medicine, University College, London, UK.

European Journal of Clinical Investigation
|June 26, 1999
PubMed
Summary
This summary is machine-generated.

Type 2 diabetes patients face higher cardiovascular disease risks due to diabetic dyslipidaemia, characterized by abnormal cholesterol and triglyceride levels. Lifestyle changes and medical treatments can effectively manage these lipid abnormalities, reducing cardiovascular disease risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).

Diabetic medicine : a journal of the British Diabetic Association·2013
Same author

Thiazolidinediones and fracture risk in patients with Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2011
Same author

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive.

Diabetes, obesity & metabolism·2011
Same author

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.

Diabetes, obesity & metabolism·2011
Same author

An Examination of Some Factors which Influence the Stability of in Vitro Platelet Responses.

Platelets·2010
Same author

Collagen-induced Platelet Activation In Vitro Increases Plasma Catecholamine Concentration.

Platelets·2010
Same journal

Pacemaker Status and 5-Year Mortality After TAVI: A Sex-Specific Analysis.

European journal of clinical investigation·2026
Same journal

Causal Effects of Time-Varying Treatments: The G-Formula.

European journal of clinical investigation·2026
Same journal

Improving Scientific Research: Renegotiated Principles of Science, Proposals, Failures, and Successes.

European journal of clinical investigation·2026
Same journal

Beta-Blockers After Myocardial Infarction With Preserved and Mildly Reduced Ejection Fraction: A Meta-Analysis With Trial Sequential Analysis.

European journal of clinical investigation·2026
Same journal

Prognostic Role of Serum Albumin Levels in Elderly Patients With Non-Valvular Atrial Fibrillation.

European journal of clinical investigation·2026
Same journal

Circulating Human Epididymis Protein 4 Predicts 10-Year Mortality and Major Adverse Cardiovascular Events in Patients With Peripheral Artery Disease.

European journal of clinical investigation·2026
See all related articles

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Type 2 diabetes significantly elevates cardiovascular disease (CVD) risk.
  • Diabetic dyslipidaemia, a key contributor, involves low HDL cholesterol and high triglycerides.
  • Qualitative changes in LDL cholesterol, including smaller, denser, and more oxidizable particles, are observed in Type 2 diabetes.

Purpose of the Study:

  • To highlight the role of diabetic dyslipidaemia in cardiovascular disease risk for Type 2 diabetes patients.
  • To describe the specific lipid profile abnormalities in Type 2 diabetes.
  • To outline strategies for managing diabetic dyslipidaemia and reducing CVD burden.

Main Methods:

  • Review of existing literature on diabetic dyslipidaemia and cardiovascular disease.

Related Experiment Videos

  • Analysis of lipid profiles in Type 2 diabetic patients compared to healthy individuals.
  • Discussion of therapeutic interventions including lifestyle modifications and pharmacotherapy.

    • Main Results:

    • Diabetic dyslipidaemia is a significant factor in the increased CVD risk associated with Type 2 diabetes.
    • Key features include low HDL, high triglycerides, and altered LDL particle characteristics (smaller, denser, more prone to oxidation).
    • Oxidized LDL is implicated in the progression of atherosclerosis.

    Conclusions:

    • Managing diabetic dyslipidaemia is crucial for mitigating CVD risk in Type 2 diabetes.
    • A combination of lifestyle interventions (physical activity, smoking cessation, weight reduction), improved glycaemic control, and hypolipidaemic drugs is effective.
    • These multifaceted strategies can reduce the overall cardiovascular burden in this high-risk population.